The vendor landscape of the global biochips market is extremely fragmented, speckled with a number of small, medium, and large enterprises. Considering that it is not a monopolistic scenario, the entry of new players is not restricted, giving vendors immense scope. In view of this, Transparency Market Research finds that despite being the leading players in the biochips market, Affymetrix Inc., Agilent Technologies Inc., and Illumina Inc. together accounted for only 40% of the global market in 2014, leaving room for a large group of contributors to collectively enjoy a 51% share in the biochips market that year.
Browse The Report: https://www.transparencymarketresearch.com/biochips-market.html
“Strategic partnerships with major industry players, the development of new and innovative products, technological advancements, and diversifying product offerings are the key strategies companies have been resorting to further their sales of biochips, penetrate into newer market areas, and gain a stronger hold over the market,” the author of the TMR study states.
Several companies have also increased focus on research and development in order to produce advanced products that align with ongoing technological shifts. Agilent Technologies is one such company. The US-based firm acquired Seahorse Bioscience, a manufacturer of tools for measuring cell metabolism, in November 2015. The acquisition has helped Agilent gain unique technological expertise that complements its mass spectrometry and separations solutions, especially in the research of metabolomics and disease. Affymetrix has also been investing large amounts of funds in the research, design, and development of new assays, arrays, and reagent products.
The rising applications of biochips in a wide range of diagnostic areas, especially in drug discovery and research and veterinary diagnostics, is a key factor boosting the global market. While the availability of molecular information and growing investments in the field will continue driving the use of biochips, TMR believes that the automation of several complex processes through the use of biochips is a major advantage that players can capitalize on.
Get Sample Copy of this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10151
The global biochips market is projected to expand at a steady 16.9% CAGR over the course of the forecast period, with the value of this market rising from US$5.7 bn in 2104 to US$22.2 bn by 2023. DNA chips form the largest segment by type in terms of revenue, with a 39.7% share in 2014. Microfluidic devices, on the other hand, are anticipated to expand at the highest CAGR of 17.4% from 2015 to 2023. Among applications, drug discovery and development is projected to witness the maximum growth through the forecast period. However, TMR predicts a slight dip in this segment’s market share. Despite this, drug discovery and development will continue to dominate the overall biochips market in terms of application.